Abstract:Purpose/Objective(s)To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy.Materials/MethodsWe conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion.ResultsA total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments.ConclusionsWe demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens. Purpose/Objective(s)To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy. To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy. Materials/MethodsWe conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion. We conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion. ResultsA total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments. A total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments. ConclusionsWe demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens. We demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens.

Abstract:Purpose/Objective(s)We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program.Materials/MethodsTwenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference.ResultsThe ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique.ConclusionsWe have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites. Purpose/Objective(s)We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program. We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program. Materials/MethodsTwenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference. Twenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference. ResultsThe ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique. The ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique. ConclusionsWe have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites. We have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites.

TH-E-M100J-04: Quantitative Assessment of Tissue Toxicity in Breast Cancer Radiation Therapy Using Spectrophotometry and Ultrasonic Tissue Characterization Imaging

Quantitative Assessment of Radiation Therapy Associated Breast Tissue Toxicity

Spectrophotometer and Ultrasound Evaluation of Late Toxicity Following Breast-Cancer Radiotherapy.

TH-D-AUD C-02: Reliability Study of Ultrasound Tissue Characterization in Quantitative Measurement of Radiation-Induced Breast Tissue Toxicity

Multimodal Photoacoustic/Elastography Imaging for the Detection of Acute Radiation Dermatitis in Breast Radiation Therapy

Noninvasive Evaluation of Breast Tumor Response to Combined Ultrasound-Stimulated Microbubbles and Hyperthermia Therapy Using Quantitative Ultrasound-Based Texture Analysis Method

Quantitative Ultrasound for Evaluation of Tumour Response to Ultrasound-Microbubbles and Hyperthermia

Preliminary Demonstration of a Radiation-dose Response Via Ultrasound-based Skin Measurements in Breast Cancer Radiotherapy

TU‐A‐WAB‐04: A Prospective Longitudinal Study with Ultrasound Nakagami Imaging to Evaluate the Relationship Between Acute and Late Normal‐Tissue Toxicity in Breast‐Cancer Radiotherapy

Potential Use of Novel Image and Signal Processing Methods to Develop a Quantitative Assessment of the Severity of Acute Radiation Dermatitis in Breast Cancer Radiotherapy

Quantitative Ultrasound Characterization of Tumor Cell Death: Ultrasound-Stimulated Microbubbles for Radiation Enhancement

Computational Model Based on Optical Coherence Tomography (OCT) Skin Scanning to Identify and Quantify Acute Radiation Dermatitis (ARD): A Prospective Diagnostic Study

Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound

Temperature Imaging with Ultrasonic Transmission Tomography for Treatment Control

Automated and Objective Assessments of Radiation-Induced Fibrosis Using Advanced Ultrasound Imaging in Breast Cancer Radiation Therapy

Ultra-Hypofractionated Whole Breast Radiotherapy with Automated Hybrid-VMAT Technique: A Pilot Study on Safety, Skin Toxicity and Aesthetic Outcomes

Preclinical multi‐physiologic monitoring of immediate‐early responses to diverse treatment strategies in breast cancer by optoacoustic imaging

Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging

Establishing Updated Safety Standards for Independent 99mTc-MAA SPECT/CT Treatment Planning in Radioembolization

Ultrasonic Tissue Microstructure Characterization Using Two-Dimensional Spectral Analysis and Its Potential Role in Conformal Radiation Therapy

INFRARED THERMAL IMAGING CONTROL OF RADIATION DERMATITIS DYNAMICS